Palvella Therapeutics (PVLA) Q2 2025 earnings summary

Executive summary

• Achieved full enrollment in the Phase 3 SELVA trial for microcystic lymphatic malformations, exceeding the target by 25%, and ongoing Phase 2 TOIVA trial for cutaneous venous malformations, with top-line results expected in Q1 2026 and Q4 2025, respectively.

• Announcements planned for a third QTORIN™ indication and a new QTORIN™ platform program in the second half of 2025, with clinical studies for new programs anticipated in the second half of 2026.

• Strengthened leadership with the addition of a Chief Commercial Officer experienced in rare disease launches and completed a reverse merger with Pieris Pharmaceuticals in December 2024, resulting in recapitalization and PIPE financing of $78.9 million.

• FDA Fast Track Designation granted for cutaneous venous malformations in 2024, and received FDA Orphan Products Clinical Trials Grant, with initial proceeds of $0.5 million and potential total of $2.6 million.

• Added to the Russell 2000 and Russell 3000 indexes in June 2025, increasing institutional visibility.

Financial highlights

• Ended Q2 2025 with $70.4 million in cash and cash equivalents, providing a runway into the second half of 2027.

• Operating expenses for Q2 2025 totaled $9.3 million, with R&D at $5.1 million and G&A at $4.1 million, reflecting increased investment in clinical and commercial activities.

• Net loss was $9.5 million for Q2 2025 and $17.7 million for the six months ended June 30, 2025.

• Projected year-end 2025 cash balance is approximately $55 million.

• No product revenue generated to date; accumulated deficit reached $111.4 million.

Outlook and guidance

• Top-line results for SELVA Phase 3 expected in Q1 2026 and for TOIVA Phase 2 in Q4 2025.

• Announcements for a third mTOR-driven QTORIN™ indication and a new QTORIN™ program planned for the second half of 2025.

• Cash runway projected into the second half of 2027, supporting current strategic agenda.

• No commercial revenue anticipated for several years; future funding needs may arise depending on development and commercialization progress.